CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Publication

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Journal Paper/Review - Aug 20, 2018

Preusser Matthias, De Mattos-Arruda Leticia, Thill Marc, Criscitiello Carmen, Bartsch Rupert, Ruhstaller Thomas, de Azambuja Evandro, Zielinski Christoph C

Citation

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski C. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open 2018; 3:e000368.

Type

Journal Paper/Review (English)

Journal

ESMO Open 2018; 3

Publication Date

Aug 20, 2018

Issn Print

2059-7029

Pages

e000368

Brief description/objective

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.